People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Participants were randomly assigned either to escalation of dulaglutide to 4.5 mg or maximum tolerated dose (MTD), or to ...

There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.